Cue Biopharma Inc (CUE)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$27.44-0.83%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · CUE
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Progress clinical development of CUE-221 with IND submission and Phase 2 data readout; initiate CUE-401 Phase 1 study by year-end 2026.
Stated as a priority in 3 of last 3 quarters. Management has consistently emphasized advancing CUE-221 clinical milestones including IND submission and Phase 2 data readout by Q3 2026, and initiating CUE-401 Phase 1 study by year-end 2026. Financially, revenue grew from $2.95M in 2025-Q2 to $7.9M in 2026-Q2, reflecting collaboration progress. The trajectory matches management's stated clinical advancement plans and milestone timing, indicating delivering progress.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 28% of the time over the next year (vs 52% for the rest of the cohort, n=10029).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Recently submitted an IND to the FDA in food allergy applications; Phase 2 data readout anticipated by end of Q3 2026; anticipate submitting IND and initiating Phase 1 study for CUE-401 by year-end 2…”
“Plan to initiate global Phase 2b trial in food allergy pending review of Ascendant Health Phase 2 CSU study; expect to submit IND and initiate Phase 1 study for CUE-401 by year-end 2026.”
“Enhanced portfolio with CUE-221; hosted R&D day on CUE-401; expect IND submission and Phase 1 initiation for CUE-401 by year-end 2026.”
Leverage exclusive license of Ascendant-221 to expand portfolio with a dual-mechanism anti-IgE antibody targeting allergic diseases.
Stated as a priority in 3 of last 3 quarters. Management executed an exclusive license agreement with Ascendant Health, paying a $15 million upfront fee and expanding the portfolio with Ascendant-221. They anticipate Phase 2 data from the China study in 2H 2026. This is reflected in increased collaboration revenue and strategic focus, indicating delivering progress on this growth priority.
“The CUE-221 license agreement augments our portfolio and opportunities; recent IND submission and financing support clinical development.”
“Enhanced the company’s portfolio with an exclusive license for CUE-221, a Phase 2 clinical anti-IgE asset from Ascendant Health Sciences Ltd.”
“Entered into exclusive license agreement with Ascendant Health Sciences Ltd. for Ascendant-221, a Phase 2 clinical stage anti-IgE antibody.”
Raise capital through private placements to fund clinical development, pipeline advancement, and infrastructure growth.
Stated as a priority in 3 of last 3 quarters. Management completed two private placements totaling approximately $80 million in Q1 and Q2 2026 to fund clinical development and corporate growth. Cash and cash equivalents were $16.4 million at 2026-Q1 and $17.4 million at 2026-Q2 after expenditures, with subsequent financing supporting runway into 2027. The trajectory shows delivering capital allocation to support operations.
“Completed a $50 million private placement to further fund clinical development and the portfolio.”
“Completed a private placement of pre-funded warrants for gross proceeds of approximately $30 million to support clinical pipeline.”
“Company estimates net proceeds from offering and existing cash will fund operations into first quarter 2027.”
Enhance management and executive team with experienced hires to support clinical and corporate strategy execution.
Stated as a priority in 3 of last 3 quarters. Management has consistently emphasized strengthening the leadership team with key executive hires including CEO, Chief Medical Officer, Head of R&D, and CFO. This aligns with the company's strategic transformation and clinical advancement plans. The trajectory shows delivering on talent acquisition to support execution.
“Strengthened leadership with appointments of Chief Medical Officer, Head of R&D, and Chief Financial Officer.”
“Appointed Shao-Lee Lin as President and CEO; added experienced executives to clinical and preclinical leadership.”
“Appointed Shao-Lee Lin as President, CEO and Board Director to lead growth and transformation.”
Collaborate with Boehringer Ingelheim on B cell depletion molecules, receiving milestone payments and advancing preclinical programs.
Over the trailing year it converted 0.92x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
27 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated volatile grew net income 53% of the time over the next year (vs 50% for the rest of the cohort, n=3986).
Not investment advice. As of 2026-09-04.